NCT00957060View on ClinicalTrials.gov

Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

GLIMEPIRIDE (HOE490)

Pharmaceutical form: 2 mg and 4 mg tablets Route of administration: oral

DRUG

SITAGLIPTIN

Pharmaceutical form: 100 mg tablets Route of administration: oral

Trial Locations (2)

Unknown

Sanofi-Aventis Administrative Office, Guatemala City

Sanofi-Aventis Administrative Office, Col. Coyoacan

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY